title: Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
abstract: Central serous chorioretinopathy (CSCR) is a challenging disease characterized by subretinal serous fluid accumulation. The complex pathogenesis is still not fully understood, but is thought to be multifactorial and involves exogenous and endogenous factors affecting the choroid and retinal pigment epithelium. The involvement of corticosteroids is undisputed, while the contribution of mineralocorticoid pathways is under investigation. This review addresses the proposed pathogenesis models and the evidence for systemic treatment of CSCR with mineralocorticoid antagonists.
authors.affiliation: a Massachusetts Eye and Ear Infirmary, Harvard Medical School , Boston , MA , USA.
authors.forename: Dong
authors.initials: D
authors.lastname: Yang
authors.affiliation: a Massachusetts Eye and Ear Infirmary, Harvard Medical School , Boston , MA , USA.
authors.forename: Dean
authors.initials: D
authors.lastname: Eliott
mesh_terms: D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D000077545:Eplerenone; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone
keywords: Chronic central serous chorioretinopathy; eplerenone; mineralocorticoid-receptor antagonist; spironolactone